% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • pfw2141 pfw2141 Nov 19, 2012 2:50 PM Flag


    I try to paste it, I hope the message boards take it.........................

    7:32AM Aeterna Zentaris: Data demonstrate that perifosine combined with temsirolimus was well tolerated in Phase 1 trial in malignant glioma (AEZS) 1.93 : Co announced that perifosine, its oral
    AKT inhibitor, combined with temsirolimus, was well tolerated in an investigator driven Phase 1 clinical trial in recurrent or progressive malignant glioma. Preliminary survival results demonstrated that median overall survival was 7.4 months. There were 27 radiographic responses: complete response (0), partial response (2), stable disease (13) and progressive disease (12). Combination therapy with TEM = 115 mg weekly and perifosine 100 mg daily (following 600 mg load) was well tolerated in heavily pre-treated adults with recurrent MGs. Accrual ongoing at dose level 5 and MTD has not yet been defined.

    Sentiment: Strong Buy

3.630.00(0.00%)Aug 30 4:00 PMEDT